2009
DOI: 10.1016/j.bmcl.2009.10.033
|View full text |Cite
|
Sign up to set email alerts
|

Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2α (HRI) kinase

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
28
0
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 38 publications
(29 citation statements)
references
References 16 publications
0
28
0
1
Order By: Relevance
“…HRI is an especially attractive target since it is not required for responses to non-pathogens but interferes with specific virulence mechanisms. Recently, it has been shown that HRI activity can be reduced by either direct targeting with small molecules or indirectly by using natural products that inhibit the HRI-cofactor Hsp90 [2830]. The targeting of host factors may make it less likely that a pathogen would evolve drug-resistance since the pathogen would not have genetic control over the interaction between the compound and its target.…”
Section: Discussionmentioning
confidence: 99%
“…HRI is an especially attractive target since it is not required for responses to non-pathogens but interferes with specific virulence mechanisms. Recently, it has been shown that HRI activity can be reduced by either direct targeting with small molecules or indirectly by using natural products that inhibit the HRI-cofactor Hsp90 [2830]. The targeting of host factors may make it less likely that a pathogen would evolve drug-resistance since the pathogen would not have genetic control over the interaction between the compound and its target.…”
Section: Discussionmentioning
confidence: 99%
“…A series of aminopyrazoloindane ATP-competitive HRI inhibitors have been reported [64]. These compounds were identified in a screen using recombinant full-length human HRI.…”
Section: Inhibitors Of Hrimentioning
confidence: 99%
“…Au cours de ces dernières années, des molécules permettant d'inhiber HRI dans une perspective thérapeu-tique ont été développées. Une équipe a développé des aminopyrazolindanes, qui inhibent HRI in vitro en entrant en compétition avec l'ATP, mais les essais effectués chez les rats ont montré une faible biodisponibilité [43]. Des études de relations structure-activité ont permis d'améliorer les propriétés pharmacodynamiques de la molécule de départ.…”
Section: Développement De Drogues Influençant L'expression De Hri Dévunclassified